BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Aer Therapeutics Raises $36M for Novel Approach to COPD

  Aer’s inhaled formulation targets the mucus plugs obstructing COPD patients’ airways.

  April 14, 2023

   · 

  3 min read

   · 

  Kate Goodwin
• 

  IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid

  California-based Acelyrin could be seeking $100 million, based on a Filing Fee Table included in its SEC filing.

  April 14, 2023

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Reformulated: New Takes on Parkinson’s Disease Treatments

  Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.

  April 14, 2023

   · 

  4 min read

   · 

  Jia Jie Chen
• 

  Drug Development

  FDA Rejects Lilly’s Ulcerative Colitis Drug over Manufacturing Concerns

  The regulator found no issues with mirikizumab’s clinical or safety data.

  April 14, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Top 2023 Neurodegenerative Readouts

  Clinical results for experimental treatments in Alzheimer’s, ALS and more are expected over the coming months. BioSpace highlights a few of the more highly anticipated datasets.

  April 14, 2023

   · 

  5 min read

   · 

  Heather McKenzie
• Lone Star Bio

  Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting

  Natera, Inc. today announced new data on its Signatera molecular residual disease (MRD) test being presented at the annual meeting of the American Association for Cancer Research (AACR) taking place April 14 – 19, 2023.

  April 14, 2023

   · 

  5 min read
• Business

  Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023

  Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its first-quarter 2023 financial results on Wednesday, May 3, 2023, prior to the open of the U.S. financial markets.

  April 14, 2023

   · 

  1 min read
• Genetown

  Vizgen’s Presentations at AACR 2023 Annual Meeting Showcase Cellular and Subcellular Tumor Characterization Using New Pre-Designed PanCancer Pathways Panel

  Vizgen today unveiled the MERSCOPE ® PanCancer Pathways Panel. The company will be presenting data generated using the PanCancer Pathways Panel at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida.

  April 14, 2023

   · 

  4 min read
• Biotech Bay

  ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress

  Company to share preclinical data on the use of integrated circuit T cells for the development of cell therapies for the treatment of kidney and other solid tumor cancers.

  April 14, 2023

   · 

  7 min read
• Business

  Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split

  Akebia Therapeutics, Inc. today announced that it will host a stockholder information session on Friday, April 21 at 8:00 a.m. ET to discuss its upcoming special meeting of stockholders.

  April 14, 2023

   · 

  5 min read